Long-Term Survival in a Patient with Malignant Carcinoid Treated with High-Dose Octreotide.

Deguchi, Hiroshi; Deguchi, Katsumi; Tsukada, Tetsuya; Murashima, Shuichi; Iwasaki, Eiichi; Tsuda, Masayuki; Kobayashi, Toshimitsu; Shirakawa, S

doi:10.2169/internalmedicine.33.100

Cited by 9 publications

(4 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Artery chemoembolization, hepatic lobectomy and octreotide treatment have all been used for the treatment of carcinoid in this patient who continues to be asymptomatic at the time of publication. A 5-year survival has also been reported in a patient with the carcinoid syndrome after octreotide administration [76]. Two cases of primary liver VIPomas treated with octreotide and followed by liver surgery also resulted in amelioration of symptoms.…”

Section: Results From Case Reportsmentioning

confidence: 85%

Octreotide for Cancer of the Liver and Biliary Tree

Kouroumalis¹

2001

Chemotherapy

View full text Add to dashboard Cite

Inoperable liver tumors have an unfavorable natural course despite various therapeutic modalities. Octreotide, a somatostatin analog, has shown considerable antitumor activity on animal models of various hepatic tumors and on isolated cell culture lines. In this paper, a review of the experimental evidence is presented. Moreover clinical papers of case reports of uncontrolled studies of patients are also reviewed. The majority of clinical studies provide evidence of a clinical and biochemical response of liver endocrine tumors while regression of tumor size is a rare event. A randomized controlled trial of octreotide in the treatment of advanced hepatocellular carcinoma has shown a significant survival benefit in the treated patients. Literature reports indicate a stimulatory effect of octreotide on Kupffer cells as a possible antitumor mechanism, but other antiproliferative actions of octreotide have been suggested but not proved. Finally the question of the presence and affinity of somatostatin receptors on liver tumor tissue is discussed. In conclusion, according to our experience, octreotide administration is the best available treatment for advanced inoperable hepatocellular carcinoma and future better patient selection, based on receptor subtypes, might further improve the results.

show abstract

Section: Results From Case Reportsmentioning

confidence: 85%

Octreotide for Cancer of the Liver and Biliary Tree

Kouroumalis¹

2001

Chemotherapy

View full text Add to dashboard Cite

show abstract

“…(Ahlman et al, 1987;Marsh et al, 1987;Roy et al, 1987;Ahlman et al, 1988a;Ockert and White, 1988;Darby et al, 1990;Debas and Mulvihill, 1994;Deguchi et al, 1994;Parry et al, 1996;Pekarek et al, 1997;Balestrero et al, 2000;Janssen et al, 2000;Kharrat and Taubin, 2003;Zimmer et al, 2003;Koopmans et al, 2005;Davi et al, 2006;Majeed et al, 2007;Papadogias et al, 2007;De Keizer et al, 2008;McPherson et al, 2009;Sinha et al, 2009;Yazbek-Karam et al, 2009;Fujie et al, 2010;Morrisroe et al, 2012;Raikhelkar et al, 2012;Shah et al, 2012;Massimino et al, 2013;van Diepen et al, 2013) The prophylactic usage of SSTA was diverse between different studies varying from long acting SSTA to continuous somatostatin infusion. Of the 28 patients with known demographic information, 17 cases (60.7%) were men and 11 cases (39.3%) were women.…”

Section: Resultsmentioning

confidence: 99%

Somatostatin Analogues Do Not Prevent Carcinoid Crisis

Guo

Tang²

2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Background: Carcinoid crisis is a life-threating syndrome of neuroendocrine tumors (NETs) characterized by dramatic blood pressure fluctuation, arrhythmias, and bronchospasm. In the era of booming anti-tumor therapeutics, this has become more important since associated stresses can trigger carcinoid crisis. Somatostatin analogues (SSTA) have been recommended for prophylactic administration before intervention procedures for functioning NETs. However, the efficacy is still controversial. The aim of this article is to review efficacy of SSTA for preventing carcinoid crisis. Materials and Methods: PubMed, Cochrane Controlled trials Register, and EMBASE were searched using 'carcinoid crisis' as a search term combining terms with 'somatostatin'; 'octreotide'; 'lanreotide' and 'pasireotide' until December 2013. Results: Twenty-eight articles were retrieved with a total of fifty-three unique patients identified for carcinoid crisis. The most common primary sites of NETs were the small intestine and respiratory tract. The triggering factors for carcinoid crisis included anesthesia/ surgery (63.5%), interventional therapy (11.5%), radionuclide therapy (9.6%), examination (7.7%), medication (3.8%), biopsy (2%) and spontaneous (2%). No randomized controlled trials (RCTs) were identified and two case-control studies were included to assess the efficacy of SSTA for preventing carcinoid crisis by meta-analysis. The overall pooled risk of perioperative carcinoid crisis was similar despite the prophylactic administration of SSTA (OR 0.44, 95% CI: 0.14 to 1.35, p=0.15). Conclusions: SSTA wasnot helpful for preventing carcinoid crisis based on a meta-analysis of retrospective studies. Attentive monitoring and careful intervention are essential. Future studies with better quality are needed to clarify any effect of SSTA for preventing carcinoid crisis.

show abstract

“…33 Side effects of subcutaneous octreotide therapy are minimal and can include fat malabsorption, pain at the injection site, rash, nausea and vomiting, abdominal discomfort, dizziness, cholestasis, and headache. 37 Octreotide is also known to cause hyperglycemia through suppression of insulin. 30,38 In a case series, octreotide-induced hyperglycemia has been shown whereby patients receiving higher doses of octreotide for surgical prophylaxis experienced elevated blood glucose and required insulin administration.…”

Section: Discussionmentioning

confidence: 99%

Mega-dose intravenous octreotide for the treatment of carcinoid crisis: a systematic review

Seymour

Sawh

2013

Can J Anesth/J Can Anesth

View full text Add to dashboard Cite

In the included case reports, carcinoid crises were managed effectively using octreotide 25-500 μg iv. Previous exposure to octreotide and carcinoid heart disease may warrant the need for higher doses. In addition to the low quality of the articles and the small sample size, inconsistent use of the term "carcinoid crisis" and paucity of reported outcomes were also limitations of this systematic review. These findings highlight the need for further investigation into dose-response relationships of octreotide for the treatment of carcinoid crisis.

show abstract

Long-Term Survival in a Patient with Malignant Carcinoid Treated with High-Dose Octreotide.

Cited by 9 publications

References 6 publications

Octreotide for Cancer of the Liver and Biliary Tree

Octreotide for Cancer of the Liver and Biliary Tree

Somatostatin Analogues Do Not Prevent Carcinoid Crisis

Mega-dose intravenous octreotide for the treatment of carcinoid crisis: a systematic review

Contact Info

Product

Resources

About